The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Impact of the type of TKI prior to allo-HSCT on outcomes in patients with Ph+ ALL
|
A retrospective, registry-based analysis assessed the impact of the type of tyrosine kinase inhibitor (TKI) used prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) on post-transplant outcomes in adult patients with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).1 This analysis included 863 patients with Ph+ ALL who were treated with imatinib (n = 606), dasatinib (n = 163), or both (n = 94).1 Results were published in Transplantation and Cellular Therapy by Giebel et al.1
|
| Key learnings |
|
At 2 years, no significant difference was observed in the pre-allo-HSCT imatinib, dasatinib, and imatinib + dasatinib treatment groups for:
|
|
While the cumulative incidences of Grade 2–4 graft-versus-host disease (GvHD) and chronic GvHD were similar between treatment groups, dasatinib was associated with a significantly higher risk of Grade 3–4 acute GvHD (20%) compared with imatinib or imatinib + dasatinib (10% vs 13%, respectively; p = 0.002). |
|
Multivariable analysis showed that dasatinib was associated with lower GvHD-free and relapse-free survival vs imatinib (hazard ratio, 1.27; 95% confidence interval, 1–1.62; p = 0.048). |
|
These findings suggest that the choice of TKI (imatinib or dasatinib) has no impact on survival after allo-HCT in Ph+ ALL; however, pre- allo-HSCT dasatinib may raise the risk of severe acute GvHD.
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
